Header Logo

Connection

CHRISTIE BALLANTYNE to Ezetimibe

Back to Details
This is a "connection" page, showing publications CHRISTIE BALLANTYNE has written about Ezetimibe.
CHRISTIE BALLANTYNE
Connection Strength
5.729
Ezetimibe
  1. Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. Eur J Prev Cardiol. 2020 04; 27(6):593-603.
    View in: PubMed
    Score: 0.621
  2. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study. Atherosclerosis. 2018 10; 277:195-203.
    View in: PubMed
    Score: 0.575
  3. Variation in Lipid-Lowering Therapy Use in Patients With Low-Density Lipoprotein Cholesterol =190 mg/dL: Insights From the National Cardiovascular Data Registry-Practice Innovation and Clinical Excellence Registry. Circ Cardiovasc Qual Outcomes. 2018 05; 11(5):e004652.
    View in: PubMed
    Score: 0.570
  4. Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance. J Clin Lipidol. 2016 May-Jun; 10(3):556-67.
    View in: PubMed
    Score: 0.486
  5. Implications for Ezetimibe Therapy Use Based on IMPROVE-IT Criteria. Am J Med. 2015 Nov; 128(11):1253-6.
    View in: PubMed
    Score: 0.467
  6. Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: A randomized phase 2 trial. J Clin Lipidol. 2023 Jul-Aug; 17(4):491-503.
    View in: PubMed
    Score: 0.203
  7. Factors Associated With Enhanced Low-Density Lipoprotein Cholesterol Lowering With Bempedoic Acid. J Am Heart Assoc. 2022 08 02; 11(15):e024531.
    View in: PubMed
    Score: 0.191
  8. Efficacy and safety of bempedoic acid in patients not receiving statins in phase 3 clinical trials. J Clin Lipidol. 2022 May-Jun; 16(3):286-297.
    View in: PubMed
    Score: 0.186
  9. Getting to an ImprOved Understanding of Low-Density Lipoprotein-Cholesterol and Dyslipidemia Management (GOULD): Methods and baseline data of a registry of high cardiovascular risk patients in the United States. Am Heart J. 2020 01; 219:70-77.
    View in: PubMed
    Score: 0.158
  10. Poststatin Lipid Therapeutics: A Review. Methodist Debakey Cardiovasc J. 2019 Jan-Mar; 15(1):32-38.
    View in: PubMed
    Score: 0.149
  11. 2017 Focused Update of the 2016?ACC?Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in?the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol. 2017 Oct 03; 70(14):1785-1822.
    View in: PubMed
    Score: 0.136
  12. Access to Nonstatin Lipid-Lowering Therapies in Patients at High Risk of Atherosclerotic Cardiovascular Disease. Circulation. 2017 05 30; 135(22):2204-2206.
    View in: PubMed
    Score: 0.133
  13. Comparative effects of cholesteryl ester transfer protein inhibition, statin or ezetimibe on lipid factors: The ACCENTUATE trial. Atherosclerosis. 2017 06; 261:12-18.
    View in: PubMed
    Score: 0.132
  14. Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients with Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol. Am J Cardiol. 2017 Feb 01; 119(3):388-396.
    View in: PubMed
    Score: 0.129
  15. Bempedoic Acid (ETC-1002): an Investigational Inhibitor of ATP Citrate Lyase. Curr Atheroscler Rep. 2016 10; 18(10):61.
    View in: PubMed
    Score: 0.128
  16. On-treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT). Am Heart J. 2016 Dec; 182:89-96.
    View in: PubMed
    Score: 0.128
  17. Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial. JAMA. 2016 Apr 19; 315(15):1580-90.
    View in: PubMed
    Score: 0.124
  18. Comparison of PCSK9 Inhibitor Evolocumab vs Ezetimibe in Statin-Intolerant Patients: Design of the Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects 3 (GAUSS-3) Trial. Clin Cardiol. 2016 Mar; 39(3):137-44.
    View in: PubMed
    Score: 0.123
  19. Influence of metabolic syndrome factors and insulin resistance on the efficacy of ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome and atherosclerotic coronary heart disease risk. Lipids Health Dis. 2015 Sep 04; 14:103.
    View in: PubMed
    Score: 0.119
  20. Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20 mg plus ezetimibe 10 mg vs. simvastatin 40 or 80 mg plus ezetimibe 10 mg in high-risk patients: Results of the GRAVITY randomized study. Atherosclerosis. 2014 Jan; 232(1):86-93.
    View in: PubMed
    Score: 0.104
  21. New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs. Eur Heart J. 2013 Jun; 34(24):1783-9.
    View in: PubMed
    Score: 0.100
  22. Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study). Am J Cardiol. 2007 Mar 01; 99(5):673-80.
    View in: PubMed
    Score: 0.065
  23. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study. Am Heart J. 2005 Mar; 149(3):464-73.
    View in: PubMed
    Score: 0.057
  24. Effectiveness and tolerability of ezetimibe add-on therapy to a bile acid resin-based regimen for hypercholesterolemia. Am J Cardiol. 2004 Sep 15; 94(6):795-7.
    View in: PubMed
    Score: 0.055
  25. Long-term safety and tolerability profile of ezetimibe and atorvastatin coadministration therapy in patients with primary hypercholesterolaemia. Int J Clin Pract. 2004 Jul; 58(7):653-8.
    View in: PubMed
    Score: 0.055
  26. Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. Am J Cardiol. 2004 Jun 15; 93(12):1487-94.
    View in: PubMed
    Score: 0.054
  27. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation. 2003 May 20; 107(19):2409-15.
    View in: PubMed
    Score: 0.050
  28. Combination therapy for combined dyslipidemia. Am J Cardiol. 2002 Nov 20; 90(10B):21K-29K.
    View in: PubMed
    Score: 0.049
  29. Use of lipid-lowering therapies in patients with chronic kidney disease and atherosclerotic cardiovascular disease: 2-year results from Getting to an imprOved Understanding of Low-Density lipoprotein cholesterol and dyslipidemia management (GOULD). Clin Cardiol. 2022 Dec; 45(12):1303-1310.
    View in: PubMed
    Score: 0.048
  30. 2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2022 10 04; 80(14):1366-1418.
    View in: PubMed
    Score: 0.048
  31. Impact of Lipid Monitoring on Treatment Intensification of Cholesterol Lowering Therapies (from the Veterans Affairs Healthcare System). Am J Cardiol. 2020 03 15; 125(6):874-879.
    View in: PubMed
    Score: 0.040
  32. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med. 2014 May 08; 370(19):1809-19.
    View in: PubMed
    Score: 0.027
  33. The Effect of Lipid Modification on Peripheral Artery Disease after Endovascular Intervention Trial (ELIMIT). Atherosclerosis. 2013 Dec; 231(2):371-7.
    View in: PubMed
    Score: 0.026
  34. Age, abdominal obesity, and baseline high-sensitivity C-reactive protein are associated with low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B responses to ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome. J Clin Lipidol. 2013 Jul-Aug; 7(4):292-303.
    View in: PubMed
    Score: 0.025
  35. Changes in prescription patterns before and after reporting of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial (ENHANCE) results and expected effects?on low-density lipoprotein-cholesterol reduction. J Clin Lipidol. 2012 Mar-Apr; 6(2):180-91.
    View in: PubMed
    Score: 0.023
  36. Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study). J Clin Lipidol. 2011 Nov-Dec; 5(6):474-82.
    View in: PubMed
    Score: 0.022
  37. Variability and persistence of aspirin response in lower extremity peripheral arterial disease patients. J Vasc Surg. 2011 Mar; 53(3):668-75.
    View in: PubMed
    Score: 0.021
  38. Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study). Am J Cardiol. 2009 Jun 15; 103(12):1694-702.
    View in: PubMed
    Score: 0.019
  39. Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy. Am J Cardiol. 2009 Feb 01; 103(3):369-74.
    View in: PubMed
    Score: 0.018
  40. Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone, and the combination of fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins. Am J Cardiol. 2008 Feb 15; 101(4):490-6.
    View in: PubMed
    Score: 0.017
  41. Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy. Curr Med Res Opin. 2007 Aug; 23(8):2009-26.
    View in: PubMed
    Score: 0.017
  42. Effectiveness and tolerability of adding ezetimibe to niacin-based regimens for treatment of primary hyperlipidemia. Endocr Pract. 2006 Mar-Apr; 12(2):159-64.
    View in: PubMed
    Score: 0.015
  43. Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia. Int J Clin Pract. 2004 Aug; 58(8):746-55.
    View in: PubMed
    Score: 0.014
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.